Dr Reddy's Laboratories Profit Margin 2010-2023 | RDY

Current and historical gross margin, operating margin and net profit margin for Dr Reddy's Laboratories (RDY) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Dr Reddy's Laboratories net profit margin as of December 31, 2023 is 19.26%.
Dr Reddy's Laboratories Annual Profit Margins
Dr Reddy's Laboratories Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $12.040B $2.992B
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $14.440B 5.21
Aspen Pharmacare (APNHY) South Africa $5.172B 0.00
BridgeBio Pharma (BBIO) United States $4.408B 0.00
Bausch Health Cos (BHC) Canada $3.088B 2.41
Amphastar Pharmaceuticals (AMPH) United States $1.963B 13.44
Supernus Pharmaceuticals (SUPN) United States $1.626B 0.00
Taysha Gene Therapies (TSHA) United States $0.460B 0.00
Generation Bio (GBIO) United States $0.187B 0.00
Assembly Biosciences (ASMB) United States $0.072B 0.00
Personalis (PSNL) United States $0.064B 0.00
Acasti Pharma (ACST) Canada $0.027B 0.00
Sol-Gel Technologies (SLGL) Israel $0.026B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00